Compare MORN & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MORN | PCVX |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | United States |
| Employees | N/A | 507 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.4B |
| IPO Year | 2004 | 2020 |
| Metric | MORN | PCVX |
|---|---|---|
| Price | $176.97 | $59.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $256.50 | $98.33 |
| AVG Volume (30 Days) | 433.4K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | ★ 3.38 | N/A |
| EPS | ★ 8.87 | N/A |
| Revenue | ★ $2,445,500,000.00 | N/A |
| Revenue This Year | $9.02 | N/A |
| Revenue Next Year | $6.34 | N/A |
| P/E Ratio | $19.49 | ★ N/A |
| Revenue Growth | ★ 7.49 | N/A |
| 52 Week Low | $149.08 | $28.09 |
| 52 Week High | $316.71 | $65.00 |
| Indicator | MORN | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 59.41 |
| Support Level | $156.37 | $42.30 |
| Resistance Level | $190.08 | $65.00 |
| Average True Range (ATR) | 6.51 | 2.13 |
| MACD | 0.39 | 0.40 |
| Stochastic Oscillator | 65.05 | 91.30 |
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.